NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Enliven Therapeutics, Inc. (ELVN) Stock Analysis

Enliven Therapeutics, Inc. (ELVN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ELVN

$41.82

+$0.57 (+1.38%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ELVN with… →

ELVN Key Statistics

As of Oct 21, 2026
Trading
Open
$41.76
Previous Close
$41.25
Day's Range
41.64–42.92
52-Week Range
14.79–62.32
Volume
2.05M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.34
Valuation
Market Cap
$3.06B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.67
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$103.69M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
73.27M
1-Year Return
+97.36%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.20M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ELVN closed at $41.82, +97.36% over 1 year.

Enliven Therapeutics, Inc. (ELVN) has a market capitalization of $3.06B.

In fiscal 2025, ELVN reported revenue of $0.00.

ELVN Stock Return by Calendar Year

Enliven Therapeutics, Inc. (ELVN) return since Mar 2020: what $10,000 became

1 year
$10,000 $19,736
+97.36%
5 years
$10,000 $29,042
+190.42%
Since Mar 2020
$10,000 $6,970
−30.30%

If you had invested $10,000 in Enliven Therapeutics, Inc. (ELVN) at the close on March 12, 2020, the earliest close on record here, it would have been worth $6,970 at the close on October 21, 2026: −30.30% in total, −5.32% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+171.56%
2025−31.56%
2024+62.57%
2023−15.40%
2022+81.78%
2021−89.80%
2020 (partial year)+47.00%

As of October 21, 2026.

ELVN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$103.69M—
2024$0.00−$89.02M—
2023$0.00−$71.58M—
2022$0.00−$37.66M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$119.66M−$103.69M—
2024$0.00—−$104.55M−$89.02M—
2023$0.00—−$83.53M−$71.58M—
2022$0.00—−$38.79M−$37.66M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Enliven Therapeutics, Inc. (ELVN) at $3.06B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 67 employees.

ELVN last closed at $41.82 on October 21, 2026. That is +$0.57 (+1.38%) against the previous close. The 52-week range on file runs from $14.79 to $62.32. The latest close sits 182.85% above that 52-week low.

Financial Health

In fiscal 2025, Enliven Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $103.69M. Earnings per share on a trailing basis come to −1.67.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is +97.36%. Across 5 years the annualized return works out at +23.77%. Beta against the wider market is reported at 0.34. Daily returns over the trailing 6 years annualize to a volatility of 84.31%.

Growth & Income

No dividend is on file for ELVN.

Across the complete calendar years on file, 2022 returned +81.78% and 2021 returned −89.80%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the total return is +171.56%.

Peer Comparison

Enliven Therapeutics, Inc. (ELVN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Enliven Therapeutics, Inc. ELVN $3.06B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Enliven Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Visit website →